Want to see CGEM full AI Analyst Report?
CGEM Stock Chart & Stats
$22.60
-$0.18(-1.04%)
At close: 4:00 PM EDT
$22.60
-$0.18(-1.04%)
Day’s Range― - ―
52-Week Range$6.73 - $23.19
Previous CloseN/A
Volume316.66K
Average Volume (3M)1.17M
Market Cap
$899.68M
Enterprise Value$796.04M
Total Cash (Recent Filing)$334.54M
Total Debt (Recent Filing)$2.07M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 05, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding64,354,690
10 Day Avg. Volume957,507
30 Day Avg. Volume1,171,532
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.82
Forecast
1Y Price Target
$35.70Price Target Upside57.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.17
Revenue Forecast (FY)$13.55M
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical EfficacyThe randomized Phase 3 result provides meaningful late-stage validation for zipalertinib in a defined lung-cancer population. A durable progression-free-survival advantage, including across subgroups, strengthens the product’s clinical differentiation and supports its potential role in first-line treatment.
Regulatory Progress And Milestone PotentialInitiating an NDA under FDA Real-Time Oncology Review advances zipalertinib toward a commercial decision and may shorten the regulatory pathway. The agreement’s contingent milestones could also provide meaningful non-dilutive funding if the targeted approvals are achieved.
Diversified Development PipelineMultiple programs across autoimmune disease and oncology give Cullinan additional development opportunities beyond zipalertinib. Upcoming multi-dose, dose-escalation and Phase 1 datasets could broaden the company’s future product base if the programs demonstrate sufficient activity and progress.
Bears Say
Pre-commercial Revenue ProfileThe absence of meaningful recurring revenue means Cullinan has not yet established a commercial cash-generating business. Until a product reaches the market and generates sales, operating performance will remain tied primarily to clinical progress, regulatory outcomes and access to external capital.
Heavy And Intensifying Cash BurnSustained cash outflows of roughly $159 million annually can reduce the resources available to fund clinical development and corporate operations. The reported intensification versus 2025 raises the risk that Cullinan may need spending reductions or additional funding before becoming self-financing.
Shrinking Equity BaseThe substantial decline in equity shows that ongoing losses and cash consumption are reducing the company’s capital base rather than compounding shareholder resources. This weakens financial flexibility over time and increases dependence on successful development milestones or future financing.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $6.73 and its highest was $23.19 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $899.68M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Nov 05, 2026 which is in 16 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Aug 06, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.011.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.84.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 64,354,690 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 1.931%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.70 (57.96% Upside)
$35.70 (57.96% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 83%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 171.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
77.97%
12-Months-Change
Fundamentals
Return on Equity
-52.89%
Trailing 12-Months
Asset Growth
-30.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cullinan Management
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM Stock 12 Month Forecast
Average Price Target
$35.70
▲(57.96% Upside)
Technical Analysis
Kura Oncology
―
Immatics
―
Janux Therapeutics Inc
―
Monte Rosa Therapeutics
―
Tyra Bioscience
―
Ownership Overview
15.75% Insiders
11.20% Mutual Funds
0.22% Other Institutional Investors
54.93% Public Companies and Individual Investors